Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache Payment policy perspectives

Neurology: Clinical Practice

Volumn 6, Issue 3, 2016, Pages 281-286

  Govindarajan, Raghav ^a   Shepard, Katie M ^b   Moschonas, Constantine ^c   Chen, Jack J ^d  

^a UNIVERSITY OF MISSOURI   (United States)

^b AMERICAN ACADEMY OF NEUROLOGY   (United States)

^c Four Peaks Neurology   (United States)

^d MARSHALL B KETCHUM UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; TIZANIDINE;

BLEPHAROSPASM; CERVICAL DYSTONIA; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; ECHOGRAPHY; ELECTROMYOGRAM; EPISODIC MIGRAINE; FUNCTIONAL ASSESSMENT; HEADACHE; HEALTH CARE POLICY; INJECTION; MUSCLE EXCITATION; MUSCLE HYPERTONIA; PHARMACEUTICAL CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE PAYMENT; REVIEW; SPASTICITY; TRANSFORMED MIGRAINE; TREATMENT INDICATION;

EID: 84974686426     PISSN: 21630402     EISSN: 21630933     Source Type: Journal    
DOI: 10.1212/CPJ.0000000000000243     Document Type: Review

References (18)

1. Assessment: botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008;70:1691-1698.
2. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008;70:1699-1706.
3. Assessment: botulinum toxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008;70:1707-1714.
4. Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010;30:793-803.
5. Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010;30:804-814.
6. Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology Epub 2016 Apr 18.
7. Hallett M, Albanese A, Dressler D, et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon 2013;67:94-114.
8. United HealthCare Botulinum Toxins A and B Drug Policy. Available at: https://www. unitedhealthcareonline. com/ccmcontent/ProviderII/UHC/en-US/Assets/ProviderStaticFiles/ ProviderStaticFilesPdf/Tools%20and%20Resources/Policies%20and%20Protocols/Medical%20Policies/ Drug%20Policies/Botulinum-toxin-policy. pdf. Accessed June 30, 2015.
9. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013;33:Section 1. 3. Available at: http://www. ihs-classification. org/-downloads/mixed/International-Headache-Classification-III-ICHD-III-2013-Beta. pdf. Accessed June 30, 2015.
10. McCrory P, Turner-Stokes L, Baguley IJ, et al. Botulinum toxin A for treatment of upper limb spasticity following stroke: A multi-centre randomized placebo-controlled study of the effects on quality of life and other person-centred outcomes. J Rehabil Med 2009;41:536-544.
11. Shaw LC, Price CI, van Wijck FM, et al; BoTULS Investigators. Botulinum toxin for the upper limb after stroke (BoTULS) trial: effect on impairment, activity limitation, and pain. Stroke 2011;42: 1371-1379.
12. Simpson DM, Gracies JM, Yablon SA, Barbano R, Brashear A; BoNT/TZD Study Team. Botulinum neurotoxin versus tizanidine in upper limb spasticity: A placebo-controlled study. J Neurol Neurosurg Psychiatry 2009;80:380-385.
13. Taylor M. Primer on botulinum toxin billing and coding: what neurologists need to know for 2014. Practical Neurology 2014. Available at: http://practicalneurology. com/2014/03/primer-on-botulinumtoxin-billing-and-coding-what-neurologists-need-to-know-for-2014/. Accessed June 30, 2015.
14. Gusev YI, Banach M, Simonow A, et al. Efficacy and safety of botulinum type A toxin in adductor spasticity due to multiple sclerosis. J Musculoskel Pain 2008;16:175-188.
15. Kaji R, Osako Y, Suyama K, Maeda T, Uechi Y, Iwasaki M; GSK1358820 Spasticity Study Group. Botulinum toxin type A in post-stroke lower limb spasticity: A multicenter, double-blind, placebocontrolled trial. J Neurol 2010;257:1330-1337.
16. Novitas Solutions. Announcement. Available at: http://www. novitas-solutions. com/cs/idcplg? IdcService5GET-DYNAMIC-CONVERSION&RevisionSelectionMethod5LatestReleased& dDocName500006151&proto5http&domain5www. novitas-solutions. com&space5MedicareJH. Accessed June 30, 2015.
17. Picelli A, Lobba D, Midiri A, et al. Botulinum toxin injection into the forearm muscles for wrist and fingers spastic overactivity in adults with chronic stroke: A randomized controlled trial comparing three injection techniques. Clin Rehabil 2014;28:232-242.
18. Lee LH, Chang WN, Chang CS. The finding and evaluation of EMG-guided BOTOX injection in cervical dystonia. Acta Neurol Taiwan 2004;13:71-76.